Correlation of MET Status with Clinicopathological Features and Prognosis of Advanced Prostatic Acinar Adenocarcinoma

HE Weiying; SUN Wenjia; LI Huiyu; ZHANG Yanggeling; WU De; AO Chunxia; WANG Jincheng; YANG Yanan; XIAO Xuexue; ZHANG Luyao; WANG Xiyuan; YUE Junqiu

doi:10.3971/j.issn.1000-8578.2025.25.0041

Cancer Research on Prevention and Treatment > 2025 > Uncorrected proof > DOI: 10.3971/j.issn.1000-8578.2025.25.0041

HE Weiying, SUN Wenjia, LI Huiyu, ZHANG Yanggeling, WU De, AO Chunxia, WANG Jincheng, YANG Yanan, XIAO Xuexue, ZHANG Luyao, WANG Xiyuan, YUE Junqiu. Correlation of MET Status with Clinicopathological Features and Prognosis of Advanced Prostatic Acinar Adenocarcinoma[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.2025.25.0041

Citation:

PDF (2684 KB)

Correlation of MET Status with Clinicopathological Features and Prognosis of Advanced Prostatic Acinar Adenocarcinoma

1.
Department of Pathology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430070, China
2.
State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing 211800, China

Funding:

undefined

2021 Wu Jieping Medical Foundation Clinical Research Special Fund (No. 320.6750.2021-21-15)

More Information

Corresponding author:
YUE Junqiu, E-mail: yuejunqiu@hotmail.com
Received Date: January 13, 2025
Revised Date: April 20, 2025
Accepted Date: April 20, 2025
Available Online: April 21, 2025

Graphical Abstract

Abstract

Abstract

Objective
To explore the correlation of MET status in patients with advanced prostatic acinar adenocarcinoma with the clinical pathological parameters and prognosis.
Methods
The specimen from 135 patients with advanced prostatic acinar adenocarcinoma was included. The expression of c-MET protein was detected via immunohistochemistry, and MET gene amplification was assessed by fluorescence in situ hybridization. The relationships of c-MET expression and gene amplification with clinicopathological features and prognosis were analyzed.
Results
The positive expression rate of c-MET was 52.60% (71/135). Compared with the c-MET expression in adjacent tissues, that in tumor tissues showed lower heterogeneous expression. Among the cases, 1.71% (2/117) exhibited MET gene polyploidy, but no gene amplification was detected. Positive c-MET expression was significantly correlated with high Gleason scores and grade groups (P=0.0073). However, no significant relationship was found between c-MET expression and progression-free survival or post-treatment t-PSA levels.
Conclusion
c-MET protein is expressed at a relatively low level in advanced prostatic acinar adenocarcinoma, suggesting that c-MET may not be a viable target for ADC drug development in prostatic acinar adenocarcinoma.
- c-MET,
- Prostate,
- Acinar adenocarcinoma,
- ADC

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (28)

References

[1]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer JClin, 2024, 74(1): 12-49. doi: 10.3322/caac.21820
[2]	Lin J, Nousome D, Jiang J, et al. Five-year survival of patients with late-stage prostate cancer: comparison of the Military Health System and the U. S. general population. Br J Cancer. 2023;128(6): 1070-6.
[3]	Golla R, Jaiswal S, Jayan A, Cheemanapalli S. Transcriptomic analysis of human castration-resistant prostate cancer: Insights into novel therapeutic strategies. Comput Biol Chem. 2025;118: 108459.
[4]	Stanislovas J, Kermorgant S. c-Met-integrin cooperation: Mechanisms, tumorigenic effects, and therapeutic relevance[J]. Front Cell Dev Biol, 2022, 10: 994528. doi: 10.3389/fcell.2022.994528
[5]	Lan Y, Liu D, Liang B, et al. ITGA3-MET interaction promotes papillary thyroid cancer progression via ERK and PI3K/AKT pathways[J]. Ann Med, 2025, 57(1): 2483379. doi: 10.1080/07853890.2025.2483379
[6]	Liu Z, Liu W, Shen X, et al. Molecular mechanism of type ib MET inhibitors and their potential for CNS tumors[J]. Sci Rep, 2025, 15(1): 6926. doi: 10.1038/s41598-025-85631-w
[7]	Gallo S, Folco CB, Crepaldi T. The MET Oncogene Network of Interacting Cell Surface Proteins[J]. Int J Mol Sci, 2024, 25(24): 13692. doi: 10.3390/ijms252413692
[8]	Yin W, Guo M, Tang Z, et al. MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome[J]. Cancers (Basel), 2022, 14(10): 2433. doi: 10.3390/cancers14102433
[9]	Colombel M, Eaton CL, Hamdy F, et al. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases[J]. Prostate, 2012, 72(7): 713-720. doi: 10.1002/pros.21473
[10]	Tripathi A, Supko JG, Gray KP, et al. Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib[J]. Clin Cancer Res, 2020, 26(23): 6122-6131. doi: 10.1158/1078-0432.CCR-20-2306
[11]	Corn PG, Zhang M, Nogueras-Gonzalez GM, et al. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer[J]. ClinCancer Res, 2020, 26(5): 990-999. doi: 10.1158/1078-0432.CCR-19-2389
[12]	Schuler M, Berardi R, Lim WT, et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial[J]. Ann Oncol, 2020, 31(6): 789-797. doi: 10.1016/j.annonc.2020.03.293
[13]	MET免疫组织化学标准化判读专家委员会, 中国抗癌协会肿瘤病理专业委员会分子病理协作组. 非小细胞肺癌MET免疫组织化学检测和判读标准中国专家共识(2023 版)[J]. 中华病理学杂志, 2023, 52(11): 1090-1097. [MET Immunohistochemistry Standardization Interpretation Expert Committee, Molecular Pathology Collaboration Group of the Tumor Pathology Professional Committee of the Chinese Anti Cancer Association. Chinese expert consensus on MET immunohistochemistry detection and interpretation standards for non-small cell lung cancer(2023 version)[J]. Zhonghua Bing Li Xue Za Zhi, 2023, 52(11): 1090-1097.] doi: 10.3760/cma.j.cn112151-20230626-00423 MET Immunohistochemistry Standardization Interpretation Expert Committee, Molecular Pathology Collaboration Group of the Tumor Pathology Professional Committee of the Chinese Anti Cancer Association. Chinese expert consensus on MET immunohistochemistry detection and interpretation standards for non-small cell lung cancer(2023 version)[J]. Zhonghua Bing Li Xue Za Zhi, 2023, 52(11): 1090-1097. doi: 10.3760/cma.j.cn112151-20230626-00423
[14]	Acker F, Klein A, Rasokat A, et al. Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition. Clin Lung Cancer. 2024;25(8): 672-82. e5.
[15]	Tsuka H, Mori H, Li B, et al. Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues[J]. Int J Oncol, 1998, 13(5): 927-934.
[16]	Pisters LL, Troncoso P, Zhau HE, et al. c-met proto-oncogene expression in benign and malignant human prostate tissues[J]. J Urol, 1995, 154(1): 293-298. doi: 10.1016/S0022-5347(01)67297-5
[17]	Watanabe M, Fukutome K, Kato H, et al. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers[J]. Cancer Lett, 1999, 141(1-2): 173-178. doi: 10.1016/S0304-3835(99)00102-0
[18]	Inoue K, Chikazawa M, Karashima T, et al. Overexpression of c-Met/hepatocyte growth factor receptors in human prostatic adenocarcinoma[J]. Acta Med Okayama, 1998, 52(6): 305-310.
[19]	Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue[J]. OncolRep, 2003, 10(5): 1149-1153.
[20]	van Leenders G, van Balken B, Aalders T, et al. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion[J]. Prostate, 2002, 51(2): 98-107. doi: 10.1002/pros.10073
[21]	Verhoef EI, Kolijn K, De Herdt MJ, et al. MET expression during prostate cancer progression[J]. Oncotarget, 2016, 7(21): 31029-31036. doi: 10.18632/oncotarget.8829
[22]	Waqar SN, Redman MW, Arnold SM, et al. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)[J]. Clin Lung Cancer, 2021, 22(3): 170-177. doi: 10.1016/j.cllc.2020.09.013
[23]	Shah MA, Bang YJ, Lordick F, et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial[J]. JAMA Oncol, 2017, 3(5): 620-627. doi: 10.1001/jamaoncol.2016.5580
[24]	Jacobsen F, Ashtiani SN, Tennstedt P, et al. High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer[J]. Exp Ther Med, 2013, 5(1): 102-106. doi: 10.3892/etm.2012.764
[25]	Guo R, Luo J, Chang J, et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy[J]. Nat Rev Clin Oncol, 2020, 17(9): 569-587. doi: 10.1038/s41571-020-0377-z
[26]	Ahn MJ, Mendoza MJL, Pavlakis N, et al. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations[J]. Clin Lung Cancer, 2022, 23(8): 670-685. doi: 10.1016/j.cllc.2022.07.012
[27]	Du M, Zhang S, Liu X, et al. Nondiploid cancer cells: Stress, tolerance and therapeutic inspirations[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(5): 188794. doi: 10.1016/j.bbcan.2022.188794
[28]	Pal SK, Tangen C, Thompson IM Jr, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet, 2021, 397(10275): 695-703. doi: 10.1016/S0140-6736(21)00152-5

[1]	SUN Pengfei, MOU Fuling, MA Li, FU Zhengfeng. Correlation Between Apparent Diffusion Coefficient and IDH-1/1p19q Genotype of Glioma[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 271-275. DOI: 10.3971/j.issn.1000-8578.2023.22.0698
[2]	WANG Hua, HU Xiaolei, LI Xingyu, DAI Ying. Advances in Combined Immunotherapy for Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 996-1002. DOI: 10.3971/j.issn.1000-8578.2022.22.0272
[3]	ZHOU Yongle, ZHANG Xuan, LI Ping, HA Minwen. Expressions of MACC1 and c-Met Proteins in Lung Adenocarcinoma and Their Correlation with Postoperative Recurrence[J]. Cancer Research on Prevention and Treatment, 2016, 43(7): 593-597. DOI: 10.3971/j.issn.1000-8578.2016.07.010
[4]	LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
[5]	SONG Wentao, SUN Yanlai. Role of Hepatocyte Growth Factor Receptor c-met Regulating Epithelial-mesenchymal Transition in Metastasis of Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(07): 737-739. DOI: 10.3971/j.issn.1000-8578.2015.07.020
[6]	ZHANG Xue-yu, ZHANG Yong-mei, YANG Cai-hong, LIU-Li-li, WU Wei. Expression of HGF，c-Met and VEGF-C in Cervical Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(04): 411-415. DOI: 10.3971/j.issn.1000-8578.2011.04.012
[7]	CHEN Zhi-hong, CHEN Hua-jun, GUO Ai-lin, AN She-juan, SU Jian, XIE Zhi, WU Yi-long. Detection of c-MET Gene Amplification in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(07): 802-805. DOI: 10.3971/j.issn.1000-8578.2010.07.018
[8]	CAO Ai-liang, CAO Pei-guo, WU Yong-jun, LI Zheng. Expression and Prognostic Significance of HGF/c-Met in Gastric Carcinoma[J]. Cancer Research on Prevention and Treatment, 2009, 36(07): 575-577. DOI: 10.3971/j.issn.1000-8578.2009.07.010
[9]	ZHANG Sheng-zhou, ZHANG Hong-xia, PAN Fei-yan, LI Chao-jun. Inhibitory Effects of Knockdown of c-Met by Adenovirus-delivered siRNA on Growth of Hepatocellular Carcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2008, 35(05): 309-312. DOI: 10.3971/j.issn.1000-8578.2852
[10]	HUANG Yi, WANG Jun-jie, RAN Wei-qiang, MA Lu-lin, CHEN Zhong-xin. Permanent ~(125)Ⅰrostate Brachytherapy Combined with Castration for Clinical Stage C Prostate Cancer(Report of 10 Cases)[J]. Cancer Research on Prevention and Treatment, 2004, 31(12): 770-772. DOI: 10.3971/j.issn.1000-8578.1580

Cited By

Cited by

Periodical cited type(4)

1.	吕星旺，魏洁. 滋肾润肺方联合化疗对晚期肺癌的临床疗效. 长春中医药大学学报. 2024(11): 1242-1246 .
2.	王倩，郑永法，戈伟. 放疗联合免疫检查点抑制剂在非小细胞肺癌中的协同作用. 医学研究杂志. 2023(01): 5-7+11 .
3.	李雪芹，张凡，李倩. 免疫检查点抑制剂同步化疗治疗非小细胞肺癌效果及对患者肿瘤标志物和免疫细胞水平的影响. 肿瘤研究与临床. 2023(02): 99-103 .
4.	湛云飞，张佳秀. 程序性死亡受体1抑制剂联合化疗治疗非小细胞肺癌的效果及其对T淋巴细胞亚群的影响. 中国当代医药. 2023(28): 83-86 .

Other cited types(4)

Figures(6) / Tables(2)

Get Citation

PDF

XML

Article views (1014) PDF downloads (258) Cited by(8)

Turn off MathJax

Article Contents

Abstract

References

Correlation of MET Status with Clinicopathological Features and Prognosis of Advanced Prostatic Acinar Adenocarcinoma